IMA (ImageneBio) Total Long-Term Assets: $14.68 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMA ImageneBio Inc IMA
10 GF Score
Price $5.59
! 3 Warning Signs
View Full Analysis

What is ImageneBio Total Long-Term Assets?

ImageneBio IMA +0.36% 10 Total Long-Term Assets is $14.68 Mil as of Mar. 2026. GuruFocus rates IMA with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. ImageneBio's Total Long-Term Assets for the quarter that ended in Mar. 2026 was $14.68 Mil.

ImageneBio Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for ImageneBio's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImageneBio Total Long-Term Assets Chart

ImageneBio Annual Data
Trend Dec23 Dec24 Dec25
Total Long-Term Assets
5.35 3.45 12.69

ImageneBio Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial 3.45 0.00 13.35 12.69 14.68
IMA
10GF Score
ImageneBio Inc IMA
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImageneBio Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of $14.68 Mil mean?
ImageneBio (IMA) has a Total Long-Term Assets of $14.68 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ImageneBio and its competitors.
Is ImageneBio's Total Long-Term Assets too high?
ImageneBio's current Total Long-Term Assets is $14.68 Mil. Overall, ImageneBio has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does ImageneBio's Total Long-Term Assets compare to HYFT and CING?
ImageneBio's Total Long-Term Assets of $14.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on ImageneBio and its competitors. ImageneBio's current Total Long-Term Assets is $14.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImageneBio stock overvalued right now?
ImageneBio (IMA) has a current Total Long-Term Assets of $14.68 Mil. The current Total Long-Term Assets is $14.68 Mil. ImageneBio's overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For ImageneBio (IMA), the current Total Long-Term Assets is $14.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImageneBio Business Description

Address 12526 High Bluff Drive, Suite 345, San Diego, CA, USA, 92130
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
10GF Score

Get the complete analysis for IMA

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.59
Price